The healthcare industry continues to underperform the broader market as firms work through legacy COVID-19 inventories. Despite these headwinds, long-term growth remains tied to digital health and pharmaceutical innovation.
- Healthcare returns of 1.8% trailed the S&P 500 by 3.1 percentage points over six months
- Surplus COVID-era inventories acted as a primary headwind through 2024
- Digital health innovation remains a key growth catalyst
- Drug development continues to drive sector evolution
Sign up free to read the full analysis
Create a free account to unlock full AI-curated market articles, personalized alerts, and more.